These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 24590727)

  • 1. Screening Ligands by X-ray crystallography.
    Davies DR
    Methods Mol Biol; 2014; 1140():315-23. PubMed ID: 24590727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fragment screening using X-ray crystallography.
    Davies TG; Tickle IJ
    Top Curr Chem; 2012; 317():33-59. PubMed ID: 21678136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
    Hennig M; Ruf A; Huber W
    Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystallographic fragment screening.
    Badger J
    Methods Mol Biol; 2012; 841():161-77. PubMed ID: 22222452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
    Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficiency of hit generation and structural characterization in fragment-based ligand discovery.
    Larsson A; Jansson A; Åberg A; Nordlund P
    Curr Opin Chem Biol; 2011 Aug; 15(4):482-8. PubMed ID: 21724447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One Question, Multiple Answers: Biochemical and Biophysical Screening Methods Retrieve Deviating Fragment Hit Lists.
    Schiebel J; Radeva N; Köster H; Metz A; Krotzky T; Kuhnert M; Diederich WE; Heine A; Neumann L; Atmanene C; Roecklin D; Vivat-Hannah V; Renaud JP; Meinecke R; Schlinck N; Sitte A; Popp F; Zeeb M; Klebe G
    ChemMedChem; 2015 Sep; 10(9):1511-21. PubMed ID: 26259992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein X-ray Crystallography and Drug Discovery.
    Maveyraud L; Mourey L
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32106588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment-based screening using X-ray crystallography and NMR spectroscopy.
    Jhoti H; Cleasby A; Verdonk M; Williams G
    Curr Opin Chem Biol; 2007 Oct; 11(5):485-93. PubMed ID: 17851109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biophysical methods for identifying fragment-based inhibitors of protein-protein interactions.
    Pfaff SJ; Chimenti MS; Kelly MJ; Arkin MR
    Methods Mol Biol; 2015; 1278():587-613. PubMed ID: 25859978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification?
    Wielens J; Headey SJ; Rhodes DI; Mulder RJ; Dolezal O; Deadman JJ; Newman J; Chalmers DK; Parker MW; Peat TS; Scanlon MJ
    J Biomol Screen; 2013 Feb; 18(2):147-59. PubMed ID: 23139382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S; Wright L; Brough P; Massey A; Hubbard RE
    Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction to fragment-based drug discovery.
    Erlanson DA
    Top Curr Chem; 2012; 317():1-32. PubMed ID: 21695633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput fragment screening by affinity LC-MS.
    Duong-Thi MD; Bergström M; Fex T; Isaksson R; Ohlson S
    J Biomol Screen; 2013 Feb; 18(2):160-71. PubMed ID: 22983162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment-based ligand discovery.
    Fischer M; Hubbard RE
    Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragments: where are we now?
    Osborne J; Panova S; Rapti M; Urushima T; Jhoti H
    Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.